The Association between Vitamin D Receptor Expression and Prolonged Overall Survival in Breast Cancer. by Ditsch, Nina et al.
 http://jhc.sagepub.com/
Journal of Histochemistry & Cytochemistry
 http://jhc.sagepub.com/content/60/2/121
The online version of this article can be found at:
 
DOI: 10.1369/0022155411429155
 2012 60: 121 originally published online 21 November 2011J Histochem Cytochem
Friese and Udo Jeschke
Nina Ditsch, Bettina Toth, Doris Mayr, Miriam Lenhard, Julia Gallwas, Tobias Weissenbacher, Christian Dannecker, Klaus
Cancer








 Official Journal of The Histochemical Society





 http://jhc.sagepub.com/cgi/alertsEmail Alerts: 
 





 What is This?
 
- Nov 21, 2011Accepted Manuscript 
 
- Jan 24, 2012Version of Record >> 
 at LMU Muenchen on June 12, 2013jhc.sagepub.comDownloaded from 
Journal of Histochemistry & Cytochemistry 60(2) 121 –129
© The Author(s) 2012




The vitamin D receptor (VDR) belongs to the nuclear class 
II receptor family of two known families (Bettoun et al. 
2003). The first one includes the estrogen, androgen, pro-
gesterone, and mineralocorticoid receptors the second one 
the thyroid (THR), vitamin D (VDR), retinoic acid (RAR), 
peroxisome proliferator-activated, and retinoid X receptors 
(RXR). It is a ligand transcription factor and mediates the 
actions of 1,25-dihydroxyvitamin D3, the active metabolite 
of vitamin D, which is involved in cell growth and differen-
tiation in normal and malignant breast tissue, where it 
shows antiproliferative effects (Perez-Fernandez et al. 
2007). VDRs are able to form heterodimers, for example, 
with RXR, THR, or RAR. These heterodimers have been 
thought to be nonpermissive because they neither bind nor 
show activation by RXR ligands (Forman et al. 1995).
In earlier studies, the expression of VDR was demon-
strated in several tissues such as breast, bone, prostate, gut, 
activated B and T lymphocytes, monocytes, and keratino-
cytes (Gombart et al. 2006). VDR is expressed in epithelial, 
stromal, and immune cells of the normal mammary gland 
and is dynamically regulated in the epithelial compartment 
during hormonal changes in puberty and pregnancy (Zinser 
and Welsh 2004). Furthermore, it is present in malignant 
429155 JHCXXX10.1369/0022155411429155Ditsch 
et al.Vitamin D Receptor and Breast Cancer Survival
2012© The Author(s) 2012
Reprints and permission:
sagepub.com/journalsPermissions.nav
Received for publication July 8, 2011; accepted October 14, 2011.
Corresponding Author:
Nina Ditsch, Department of Obstetrics and Gynecology–Großhadern, 
Ludwig-Maximilians-University, Marchioninistr. 15, D-81377 Munich, 
Germany. 
E-mail: nina.ditsch@med.uni-muenchen.de
The Association between Vitamin D Receptor Expression and 
Prolonged Overall Survival in Breast Cancer
Nina Ditsch, Bettina Toth, Doris Mayr, Miriam Lenhard, Julia Gallwas, Tobias 
Weissenbacher, Christian Dannecker, Klaus Friese, and Udo Jeschke
Department of Obstetrics and Gynecology–Großhadern (ND,ML,JG,CD,KF), Department of Pathology (DM), and Department of Obstetrics and 
Gynecology–Maistrasse (TW,KF,UJ), Ludwig-Maximilians-University, Munich, Germany, and Department of Gynecological Endocrinology and Fertility 
Disorders, Ruprecht-Karls University, Heidelberg, Germany (BT).
Summary
In this study, we analyzed vitamin D receptor (VDR) expression and survival in a breast cancer patient cohort of 82 breast 
cancer patients. Immunohistochemical analysis was possible in 91.5% of the patients (75/82). Staining was evaluated using the 
semi-quantitative assay according to Remmele and Stegner (immunoreactivity score [IRS]). IRS 0–1 was negative/very low, IRS 
2–4 was moderate to high, and IRS 6–12 was high. Statistical analysis was performed by Spearman’s correlation test (p<0.05 
significant). Overall survival was analyzed using Kaplan-Meier estimations. Only 6 patients had a negative IRS. Moderate IRS 
values were present in 20 patients. Most of the patients had a high IRS (49). For survival analysis, data were dichotomized 
(IRS 0–4: negative to moderate and IRS 6–12: high VDR expression). In univariate analysis, VDR expression showed significant 
differences in progression-free survival (PFS) and overall survival (OS). Patients with high IRS scores showed significantly better 
PFS and OS than patients with moderate/negative IRS scores for VDR expression. Tumor size was significantly correlated to 
PFS. When analyzed separately, the three different IRS groups showed significant differences in VDR expression. The present 
data suggest that VDR expression in breast cancer tissue may be of clinical significance, and the results provide evidence that 
VDR may be a factor with prognostic relevance. (J Histochem Cytochem 60:121–129, 2012)
Keywords
breast cancer, vitamin D receptor, immunohistochemistry, prognosis
Article
 at LMU Muenchen on June 12, 2013jhc.sagepub.comDownloaded from 
122  Ditsch et al.
dividing cell types, responding to 1,25 vitamin D3 (Gombart 
et al. 2006). Beside VDR expression in most of the breast 
cancer cell lines (Frampton et al. 1982), there is an upregu-
lation of VDR at the protein level in breast carcinoma as 
compared to normal breast tissue (Friedrich et al. 2002). A 
higher VDR expression in tumors seems to be correlated 
with a better prognosis in cancer patients (Berger et al. 
1991). This could be dependent on the active forms of vita-
min D, which is known to be an inhibitor of growth and is 
able to induce apoptosis (Narvaez and Welsh 2001; Friedrich 
et al. 2002; Matthews et al. 2010).
In the present study, immunohistochemical staining of 
VDR in paraffin-embedded malignant breast tissue was 
associated with the clinical pathological findings of these 
tumors. Furthermore, this investigation was performed to 




Breast cancer samples from 82 patients of the Department 
of Gynaecology and Obstetrics of the Ludwig Maximilian 
University of Munich, Germany, were included in this 
study after permission from the local Ethics Committee. 
Paraffin-embedded tissues were sampled between 1990 and 
2000 from patients with a first diagnosis of breast cancer. 
Patients fulfilling the inclusion criteria were chosen on the 
basis of equal distribution among certain clinical patho-
logical findings such as lymph node involvement, histo-
pathological type (invasive ductal), and as far as possible 
estrogen/progesterone receptors (Fig. 1). All tumor samples 
were classified by the TNM system (Boecker 2002). The 
histological classification was determined according to a 
modification of the Elston and Ellis grading proposed by 
Bloom and Richardson (Elston and Ellis 1991). The hor-
mone receptor status was evaluated by immunohistochem-
istry. The tumor was classified as hormone receptor 
positive in case of positive staining in ≥10% of the tumor 
cell nuclei. Dissection of axillary lymph nodes was carried 
out in all of the patients. Only patients with immunostain-
ing evaluable for VDR were chosen for further analysis. 
The age of the patients ranged between 54 and 95 years. All 
of the patients were postmenopausal.
Clinical and Histopathological Data
The distribution of clinical and histopathological data such 
as tumor size, axillary node involvement, grading, estro-
gen-progesterone receptor (ER/PR) status, and Her-2 
expression is presented in Table 1. Because of the tissue 
detachment in seven slides, data were evaluable only in 75 
Figure 1. Patient cohort.
Table 1. Tumor Data of the Patient Cohort
Clinical Pathological Data n %
Tumor size (pT)
 pT1a   1 1.3
 pT1b 14 18.7
 pT1c 40 53.3
 pT2 16 21.3
 pT3  0 0
 pT4  4 5.4
Axillary LNI
 Positive 34 45.4
 Negative 41 54.6
Grading
 1  8 10.7
 2 36 48
 3 31 41.3
Hormone receptors (ER/PR)
 Positive 41 54.6
 Negative 34 45.4
Her-2
 Positive 15 20
 Negative 54 72
p, pathological classification; LNI, lymph node involvement; ER, estrogen 
receptor; PR, progesterone receptor; n, number of patients.
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of 82 patients. Her-2 expression was reexamined by immu-
nohistochemistry. Values of 0 and 1 were considered nega-
tive, values of 3+ were classified as positive, and in case of 
2+, a fluorescence in situ hybridization was performed. As 
retrospectively analyzed, most patients had a negative 
Her-2 status. In six patients, it was not possible to deter-
mine Her-2 expression because of missing tissue.
Very small tumors were rare; most patients had a pT1c. 
The other clinical and pathological parameters were simi-
larly distributed to data known from the literature.
All of the ER/PR-positive patients received antihor-
monal therapy.
VDR-positive results showed brownish staining of the 
nucleus and cytoplasm. Slides were considered negative 
when the immunoreactivity score (IRS) was 0–1, moder-
ately positive when IRS was 2–4, or highly positive when 
IRS was 6–12. To simplify statistical analysis, data had to 
be dichotomized because the number of patients and events 
in the 0–1 IRS group was small.
Of 75 patients, immunohistochemical analysis revealed 
VDR-positive tumors in 69 (92%) of all tissues investigated 
(Fig. 2A,B). Six patients (8%) showed no expression of 
VDR (IRS 0–1). Moderate IRS values were presented in 20 
patients (26.7%): IRS value of 2 was presented in 2 (2.7%), 
IRS of 3 in 8 (10.7%), and IRS of 4 in 10 (13.3%) of these 
patients. Most of the patients had a high IRS (65.3%)—an 
IRS of 6 was prevalent in 9 (12%), an IRS of 8 in 16 
(21.3%), an IRS of 9 in 5 (6.7%), and an IRS of 12 in 19 
(25.3%).
Correlations of VDR with Clinical Pathological 
Findings
On correlation analysis, VDR showed negative associa-
tions with tumor size (Spearman rho [SR] = –0.278, 
p=0.016) and lymph node involvement (SR = –0.411, 
p<0.01). No correlation was found with regard to grading 
(SR = –0.044, p=0.706), estrogen/progesterone receptor 
status (SR = 0.067, p=0.567), and Her-2 expression (SR = 
–0.006, p=0.959).
Progression-free and Overall Survival
Until 2010, we were able to collect current follow-up data 
for 65 of 75 patients (86.67%). Overall, 22 of 75 (29.3%) 
patients had recurrent disease since 1990; 18 of these 
patients had hematogenous metastatic disease, 12 had local 
recurrence, and 5 presented with contralateral breast can-
cer. Twenty-four (32%) of the breast cancer patients died, 
most of them due to metastatic disease.
Immunohistochemistry
Samples were processed for immunohistochemistry using a 
combination of pressure cooker heating and the standard 
streptavidin-biotin-peroxidase complex with the mouse 
IgG-Vectastain Elite ABC kit (Vector Laboratories; 
Burlingame, CA). Sections of 5 µm thickness were deparaf-
finized, hydrated, and incubated using xylol for 15 min; 
rehydrated in a descending series of alcohol (100%, 96%, 
and 70%); and, for antigen retrieval, incubated for 10 min 
using sodium citrate buffer (pH 6.0) containing 0.1 M citric 
acid and 0.1 M sodium citrate in distilled water. After wash-
ing in PBS, endogenous peroxidase activity was blocked by 
immersion in 3% hydrogen peroxide (Merck; Darmstadt, 
Germany) in methanol for 20 min. To prevent nonspecific 
binding of the primary antibody, the sections were incu-
bated with diluted normal serum (10 ml PBS containing 
150 µl horse serum; Vector Laboratories) for 20 min at 
room temperature. Sections were then incubated at room 
Figure 2. (A, B) Immunohistochemical staining 
of vitamin D receptor (VDR) in human breast 
cancer. The illustrations show immunoreaction 
after incubation with the primary antibody of the 
cells of the malignant breast tumors (25× lens). 
(A) Negative/low immunoreactivity score (IRS) 
and (B) high IRS. (C, D) Placental tissue serves 
as negative and positive control for VDR. For 
negative controls (blue), isotype-matching control 
antibodies of the same species were used (C). 
Positive control (D) shows VDR staining of villous 
trophoblast cells. Bars = 100 µm.
 at LMU Muenchen on June 12, 2013jhc.sagepub.comDownloaded from 
124  Ditsch et al.
temperature for 60 min with the vitamin D antibody (mono-
clonal, clone 2F4, isotype IgG2a, AbD Serotec, MCA 
3543Z) concentration of 0.5 mg/ml and diluted 1:100 in 
biotinylated serum (10 ml PBS containing 50 µl horse 
serum; Vector Laboratories) for 30 min at room tempera-
ture. Incubation was performed with the avidin-biotin-per-
oxidase complex (diluted in 10 ml PBS; Vector Laboratories) 
for 30 min. The chromagen 3,3′-diaminobenzidine (DAB; 
Dako, Glostrup, Denmark) was used for 8 to 10 min for 
visualization. Sections were counterstained with Mayer’s 
acidic haematoxylin, dehydrated, and covered.
Negative and positive controls (placental tissue) were 
used to assess the specificity of immunoreactions. For nega-
tive controls (colored blue), isotype-matched control anti-
bodies of the same species (DAKO, Hamburg, Germany) 
were applied on breast cancer tissue that showed high VDR 
IRS expression (Fig. 2C). Negative control tissue showed 
neither nuclear nor cytoplasmic staining. On the other hand, 
it could be demonstrated that cytoplasmic staining was also 
specific. Positive cells showed a brownish color (Fig. 2D). 
Negative controls as well as unstained cells appeared in 
blue.
The IRS was assigned according to Remmele and 
Stegner (1987). The assessment of the degree of staining 
and distribution patterns of specific immunohistochemical 
staining were evaluated using a semi-quantitative assay as 
used for ER/PR receptors (Jeschke et al. 2005; Mylonas 
et al. 2005). The IRS was calculated by multiplication of the 
staining intensity. The percentage of cells with positive 
staining was scored as follows: 0 = no, 1 = weak, 2 = mod-
erate, and 3 = strong staining; the percentage of positively 
stained cells was scored as follows: 0 = no staining, 1 = <10% 
of cells, 2 = 11% to 50% of cells, 3 = 51% to 80% of cells, 
and 4 = >81% of cells stained. The total score per sample 
therefore ranged from 0 to 12; 0 to 1 indicates no staining 
(e.g., negative results), 2 to 4 indicates moderate staining, 
and 6 to 12 indicates high staining. This evaluation was 
based on the original Remmele and Stegner (1987) charac-
terization for hormone receptors in breast cancer. The slides 
were examined in a blinded way by the same experienced 
investigators using a CCD color camera (JVC, Victor 
Company of Japan; Yokohama, Japan) and a Leitz (Wetzlar, 
Germany) microscope.
Statistical Analysis
Statistical analysis was performed with PASW version 18.0 for 
windows (PASW; Chicago, IL) using Spearman’s correlation 
test. A 5% significance level was adopted. Independent vari-
ables were analyzed by the Mann-Whitney U test and Kruskal-
Wallis test, respectively. Univariate analysis was done with 
encoding items. Progression-free and overall survival was 
analyzed using Kaplan-Meier estimations. Multivariate mod-
els were analyzed by Cox regression analysis.
Results
Data analyses included the evaluation of progression-free 
survival and overall survival. The univariate and multivari-
ate model was used to show the prognostic relevance of the 
clinical and histopathological parameters. For Cox regres-
sion and Kaplan-Meier analysis, data were dichotomized 
(IRS 0–4 vs IRS 6–12). Furthermore, the intensity of scor-
ing and the percentage of cells staining positive were 
assessed independently for correlation with outcome.
Progression-free Survival
Univariate analysis (Table 2) showed significant results for 
VDR (p=0.046) and of the known prognostic parameters 
for tumor size (pT) (p=0.001) and lymph node involvement 
(p=0.009). When separately analyzed for intensity and per-
centage of VDR-positive cells, significant differences were 
present only for the percentage of positive stained cells 
(p=0.001) in contrast to the intensity of VDR (p=0.131). 
For all other parameters, no significant differences could be 
demonstrated.
As shown in Kaplan-Meier curve (Fig. 3A), patients 
with higher IRS (6–12) showed a significantly higher pro-
gression-free survival (PFS; log rank p=0.037 after dichoto-
mization). Mean PFS differed between 8.4 years for the IRS 
0–4 group and 14.3 years for the IRS 6–12 group. After a 
follow-up time of 12 years, about 70% of the patients with 
an IRS of 6–12 lived progression free in contrast to 50% of 
the patients with an IRS of 0–4. If data were analyzed sepa-
rately for intensity of scoring and percentage of cells, sur-
vival rates differed (Fig. 3B,C). With regard to intensity, no 
significant differences for VDR expression could be seen 
between the groups of 0–1 or 2–3 (log rank p=0.119). In 
contrast, highly significant differences (log rank p=0.000) 
were demonstrated for a higher percentage of VDR expres-
sion (50%–100%) in contrast to results less than 50%.
In multivariate analysis for the dichotomized IRS group, 
as for the selected analysis of intensity and percentage of 
cells stained positive (Table 2), only one of the parameters 
proved to be a prognostic factor for PFS (tumor size, 
p=0.006). VDR could not assert itself as a factor with prog-
nostic importance (p=0.436; hazard ratio [HR] = 0.67; 95% 
confidence interval [CI], 0.24–1.9). This could also be dem-
onstrated for separate analysis of intensity and percentage 
of positive-stained cells.
Overall Survival
As shown for PFS, VDR expression also showed signifi-
cant differences in univariate analysis (p=0.014). When 
separately analyzed for intensity and percentage of positive 
cells, VDR showed significant differences (p=0.037 and 
p=0.007). Furthermore, tumor size (p=0.010) and lymph 
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node involvement (p=0.028) showed significant differ-
ences. The other known prognostic factors showed non-
significance (Table 3).
Significantly better survival could be demonstrated sep-
arately for high IRS (log rank p=0.008; Fig. 3D), staining 
intensity (log rank p=0.028; Fig. 3E), and percentage of 
Table 2. Univariate and Multivariate Analysis—Disease-free Survival
Histopathological Parameters p (uv) HR (uv) 95% CI (uv) p (mv) HR (mv) 95% CI (mv)
Tumor size (pT) 0.001 4.62 1.94–11.02 0.006 1.51 1.12–2.02
Lymph node involvement (LNI) 0.009 3.53 1.37–9.12 0.208 2.11 0.66–6.78
Grading 0.468 1.28 0.66–2.49 0.790 1.11 0.50–2.46
Estrogen/progesterone receptors 0.835 0.91 0.38–2.17 0.964 1.08 0.41–2.81
Her-2 0.954 0.97 0.33–2.88 0.964 0.97 0.30–3.19
VDR (IRS) dichotomized 0.046 0.83 0.73–0.94 0.436 0.67 0.24–1.9
VDR (three IRS groups) 0.003 0.83 0.73–0.94 0.187 0.58 0.26–1.3
VDR (intensity) 0.131 0.51 0.22–1.22 0.786 0.87 0.31–2.45
VDR (percentage of positive stained cells) 0.000 0.19 0.08–0.46 0.110 0.41 0.13–1.22
uv, univariate analysis; mv, multivariate analysis; HR, hazard ratio; CI, confidence interval; IRS, immunoreactivity score; VDR, vitamin D receptor; bold 
numbers, significant p-values.
Figure 3. (A) Progressive-free survival (PFS) shown in Kaplan-Meier curves of two different vitamin D receptor groups classified as negative 
and moderately positive (0–4 immunoreactivity score [IRS]) or highly positive IRS (6–12 IRS). (B) Overall survival (OS) shown in Kaplan-Meier 
curves of two different vitamin D receptor groups classified as negative and moderately positive (0–4 IRS) or highly positive (6–12 IRS). (C) 
PFS shown in Kaplan-Meier curves of two different vitamin D receptor groups for intensity of staining (0–1 vs 2–3). (D) OS shown in Kaplan-
Meier curves of two different vitamin D receptor groups for intensity of staining (0–1 vs 2–3). (E) PFS shown in Kaplan-Meier curves of two 
different vitamin D receptor groups for percentage of cells staining positive (0%–50% vs 50%–100%). (F) OS shown in Kaplan-Meier curves of 
two different vitamin D receptor groups for percentage of cells staining positive (0%–50% vs 50%–100%).
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cells positively stained (log rank p=0.003; Fig. 3F). Mean 
survival was longer in the IRS 6–12 versus the IRS 0–4 
group (15.3 vs 10.4 years).
None of the prognostic factors yielded significant differ-
ences (Table 3). For VDR, a trend for a better overall sur-
vival (OS) could be demonstrated (p=0.060; HR = 0.39; 
95% CI, 0.14–1.04).
If analysis were done separately for the three groups 
named above (IRS 0–1, IRS 2–4, and IRS 6–12), significant 
results could be demonstrated for VDR (Table 3). Separate 
analysis of intensity and percentage of positive-stained cells 
of VDR showed non-significant results (Table 3).
Discussion
The results obtained in this study show that VDR expres-
sion is negatively associated with tumor size and lymph 
node involvement on bivariate correlation analysis. 
Furthermore, VDR expression was a factor with prognostic 
relevance on univariate analysis. A better outcome was seen 
in patients with high VDR-IRS than in patients with low 
IRS. However, after dichotomization in two VDR groups 
(IRS 0–4 and IRS 6–12), there was only a trend for a better 
OS. If the same analysis had been done for the three differ-
ent IRS groups, significant results for OS would have been 
present. For this patient cohort, separate analysis of inten-
sity, percentage of cells of VDR, and IRS results showed 
that results probably were influenced mainly by the per-
centage of positive-stained cells.
VDR, a nuclear transcription-regulating factor that belongs 
to the steroid hormone superfamily, is encoded by genes. The 
most well-studied gene is VDRG (vitamin D receptor gene). A 
few of its single-nucleotide polymorphisms (SNPs) such as 
Fok1, Bsm1, Taq1, and Poly (A) have been extensively studied 
(McCullough et al. 2009). All opposed data for associations 
with breast cancer were demonstrated, but in the case of Fok1, 
a large pooled analysis of 2009 associations with the Fok1 
SNP was slightly stronger for localized invasive cases and did 
not vary by ER/PR tumor type or menopausal status (McKay 
et al. 2009). In contrast, data from a cohort of Caucasian 
women showed a higher breast cancer risk for the Bsm1bb 
genotype only for postmenopausal women (Trabert et al. 
2007). On the basis of recent data, McCullough et al. (2009) 
stated an important role for vitamin D and its receptor for 
breast cancer in humans.
VDR is involved in cell growth and differentiation in 
normal and breast cancer tissue. VDR is expressed in epi-
thelial, stromal, and immune cells of the mammary gland. 
In the epithelial compartment, it is dynamically regulated in 
special hormonal phases such as puberty and pregnancy 
(Zinser et al. 2002; Zinser and Welsh 2004). Animal models 
have shown that a lack of VDR expression is associated 
with alterations in proliferation and apoptosis of the epithe-
lial cells (Zinser et al. 2005).
In a variable number of cases of infiltrative carcinoma, 
immunostaining of VDR occurred in the nucleus (Conde 
et al. 2004). Our data underline these findings with mainly 
nuclear VDR expression in breast cancer tissue samples.
We found a correlation between a better prognosis in 
patients with higher VDR IRS in contrast to patients 
with very low or no VDR expression. Only one study was 
found that investigated the immunocytochemical detec-
tion of the VDR in breast cancers: Berger et al. (1987) 
used an immunocytochemical technique to demonstrate 
the 1,25(OH)2D3 receptor in 80% of breast tumor cells. 
Our data are consistent with this result, with an approxi-
mately 90% positive VDR detection in breast cancer tissue 
by immunohistochemistry. The study by Berger et al. also 
demonstrated an association between higher tumor VDR 
expression and better prognosis (Berger et al. 1991), 
which was demonstrated by significantly earlier disease 
relapse in VDR-negative tumors than in VDR-positive 
tumors (p=0.045), but VDR was not related to overall sur-
vival (p>0.1).
Our study showed a trend for prediction of overall sur-
vival in contrast to previous studies (Freake et al. 1984; 
Table 3. Univariate and Multivariate Analysis—Overall Survival
Histopathological Parameters p (uv) HR (uv) 95% CI (uv) p (mv) HR (mv) 95% CI (mv)
Tumor size (pT) 0.010 1.45 1.09–1.93 0.072 1.35 0.97–1.86
Lymph node involvement (LNI) 0.028 2.60 1.11–6.17 0.428 1.60 0.50–5.08
Grading 0.727 1.12 0.59–2.12 0.940 0.97 0.43–2.18
Estrogen/progesterone receptors 0.532 0.77 0.34–1.75 0.732 0.85 0.33–2.19
Her-2 0.515 1.40 0.51–3.82 0.544 1.41 0.47–4.18
VDR (IRS) dichotomized 0.014 0.35 0.15–0.81 0.060 0.39 0.14–1.04
VDR (three IRS groups) 0.002 0.38 0.20–0.72 0.034 0.45 0.21–0.94
VDR (intensity) 0.037 0.42 0.18–0.95 0.147 0.49 0.18–1.29
VDR (percentage of positive stained cells) 0.007 0.29 0.12–0.71 0.278 0.55 0.18–1.63
uv, univariate analysis; mv, multivariate analysis; HR, hazard ratio; CI, confidence interval; IRS, immunoreactivity score; VDR, vitamin D receptor; bold 
numbers, significant p-values.
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Eisman et al. 1986; Berger et al. 1991) and no effect on 
disease-free survival, in contrast to Berger et al. (1991). 
There is evidence (Freake et al. 1984; Eisman et al. 1986) 
that the effect could depend on the large, positively stained 
proportion of VDR and therefore the potential responsive-
ness of vitamin D (Berger et al. 1991). Otherwise, a link 
could exist between the established histopathological 
parameters and VDR expression (e.g., high levels of VDR 
correlated with small tumor sizes).
VDR is upregulated in breast carcinomas at the protein 
level as compared to normal breast tissue (Conde et al. 
2004), indicating a possibly increased sensitivity to thera-
peutically administered vitamin D analogues (Friedrich 
et al. 2002). It is known that most dividing cell types 
expressing VDR respond to 1,25(OH)2D3 (Gombart et al. 
2006). Preclinical and ecologic studies support a role of 
vitamin D in the prevention of breast and other cancer types 
(Welsh et al. 2002; Zhang et al. 2005). A prospective analy-
sis of breast cancer incidence in relation to vitamin D intake 
in over 30,000 women in the Women’s Health Study indi-
cated a moderate association between a lower breast cancer 
risk for premenopausal women and a higher vitamin D 
intake but was unable to confirm these findings for post-
menopausal women (Lin et al. 2007). Further results of 
large cohort studies focused on postmenopausal status and a 
vitamin D intake of >800 IU/d could show a possible asso-
ciation with a decrease in risk of breast cancer (Robien et al. 
2007). Previous data showed that a relatively noncalcemic 
analogue of vitamin D, 1-alpha-hydroxy-24-ethyl-cholecal-
ciferol, is a promising chemopreventive agent in experimen-
tal mammary carcinogenesis models (Hussain et al. 2006).
Until now, the research data have been inconsistent and 
do not help to establish a cause-effect relationship (Colston 
2008; Chung et al. 2009; Manson et al. 2011).
As shown in previous studies, we confirm that there is no 
correlation between the presence of VDR and ER/PR 
(Freake et al. 1984; Ulmann et al. 1984; Berger et al. 1987). 
However, in contrast to other studies (Clark et al. 1983; 
Mason et al. 1983; Howat et al. 1985), we were unable to 
demonstrate prognostic relevance for ER/PR expression, 
which might be due to the inclusion of the small number of 
patients. Data of vitamin D intake and breast cancer inci-
dence or prognosis still showed heterogeneous results for 
postmenopausal patients (Robien et al. 2007; Chlebowski 
et al. 2008). The data also differed from results of premeno-
pausal women (Lin et al. 2007). Therefore, ongoing research 
of VDR expression will include a larger cohort of patients, 
including premenopausal women. Furthermore, for confir-
mation of a “dose-response” with the IRS, a larger patient 
cohort that is separately evaluated for intensity and percent-
age of positive staining of cells is needed.
The strengths of our study are the consistent histopathology 
review by expert gynecologic oncology pathologists and the 
long follow-up time. The weakness of our study is the small 
number of patients, which could be one of the reasons for the 
different results in multivariate analysis after dichotomization. 
Therefore, caution is needed in the interpretation of the data 
because of the failure of VDR measurement in the peripheral 
blood of the breast cancer patients at the time of tumor biopsy 
due to the retrospective nature of the study.
Conclusion
VDR expression is a factor associated with clinical prog-
nostic factors such as tumor size and lymph node involve-
ment. Furthermore, VDR expression showed significant 
results on univariate analysis and a trend for being of prog-
nostic relevance in multivariate analysis. The presence of 
VDR may be of clinical significance, and the results pre-
sented here may provide evidence that VDR is a factor with 
prognostic relevance that may therefore serve as a new 
target for innovative cancer therapies. Prospective studies 
are part of ongoing research, including measurement of 
vitamin D in peripheral blood.
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